FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

作者：Prokop Vodička, Matthew J. Maurer, Michal Masar, Yucai Wang, Andrea Janíková, Izidore S. Lossos, David Belada, Jonathon B. Cohen, Aleš Obr, Eric Mou, Heidi Móciková, Carla Casulo, Juraj Ďuraš, Chijioke Nze, Kateřina Steinerová, Dilan A. Patel, Josef Karban, Peter Martin, David Šálek, Andrew L. Feldman, Alice Šýkorová, Elliot Cahn, Magdalena Klánová, Vít Campr, David L. Jaye, Jozef Michalka, Pavla Štěpánková, Sergei Syrbu, Samuel Hricko, Alexandra Suri, Melissa C. Larson, Radek Jakša, Jitka Dlouhá, Thomas Habermann, Petra Blahovcová, Christopher R. Flowers, Pavel Klener, Vít Procházka, James R. Cerhan, Marek Trněný · 发表于：Blood · 年份：2025 · DOI：10.1182/blood-2025-1826 · 被引用次数：1 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research

Abstract Introduction Marginal zone lymphoma (MZL) is an indolent and heterogenous disease. Several prognostic models have been proposed to assess outcomes in MZL, including FLIPI, IPI (primarily designed for overall survival [OS]), and MZL-specific scores such as MALT-IPI (event-free survival [EFS]) and MZL-IPI (progression-free survival). FLIPI24 is a recently developed prognostic index for patients with follicular lymphoma (FL) treated with first-line (1L) immunochemotherapy (IC), identifying a high-risk population with inferior survival and increased risk of lymphoma-related death. FLIPI24 has also demonstrated robust performance in the entire FL population, including patients under observation. This study aimed to evaluate the prognostic utility of FLIPI24 in patients with MZL and to compare its performance with other established indices (FLIPI, MZL-IPI, IPI, MALT-IPI). Methods We pooled harmonized data from newly diagnosed MZL patients with complete available FLIPI24 variables (age, white blood cell count [WBC], hemoglobin [HGB], serum lactate dehydrogenase [LDH], and beta-2-microglobulin [B2M] levels) treated with 1L IC. Data were collected from three prospective international cohorts: NiHiL (Czech Republic; n=897; enrolled 2005–2023), LEO (USA; n=62; 2015–2020), and MER (USA; n=32; 2010–2015), forming a pooled cohort of 991 1L IC-treated patients. The analysis was then extended to include all newly diagnosed MZL patients (n=2,116), regardless of treatment. The primary...